米诺环素、替加环素对多重耐药菌的体外抗菌活性比较  

Comparative in vitro activity of tigecycline and minocycline against multidrug-resistant clinical isolates

作　　者：梁慧[1] 彭国钧[1] 张薇[1] 刘佳[1] 王海燕[1] 王秀梅[1] 郝钦芳[1] 胡红焱[1] 

机构地区：[1]武警总医院检验科,北京100039

出　　处：《中国感染与化疗杂志》2012年第5期390-392,共3页Chinese Journal of Infection and Chemotherapy

基　　金：武警总医院苗圃基金NDM-1超级细菌筛选与临床应用(WZ2010049号)

摘　　要：目的评价米诺环素、替加环素对多重耐药的耐甲氧西林金葡菌(MRSA)、肠球菌和鲍曼不动杆菌的体外抗菌活性。方法采用微量肉汤稀释法测定临床分离的多重耐药细菌对米诺环素、替加环素的敏感性。结果多重耐药的1 55株鲍曼不动杆菌,99株(63.9%)对米诺环素敏感,39株(25.2%)对米诺环素耐药,17株(11.0%)对米诺环素中介。75株多重耐药MRSA,50株(66.7%)对米诺环素敏感,20株(26.7%)对米诺环素中介,5株(6.7%)为耐药株。93株多重耐药屎肠球菌中36株(38.7%)对米诺环素敏感,57株(61.3%)对米诺环素耐药。39株粪肠球菌中25株(64.1%)对米诺环素敏感。75株MRSA对替加环素100%敏感,132株肠球菌100%敏感。5株耐万古霉素屎肠球菌和4株产新德里金属β内酰胺酶不动杆菌全部对替加环素敏感,MRSA和肠球菌对替加环素敏感性为100%。结论替加环素对米诺环素耐药的肠球菌和MRSA有很好的体外抗菌活性,替加环素对米诺环素耐药的鲍曼不动杆菌的抗菌活性也不理想。Objective To compare the in vitro activity of tigecycline and minocycline against multidrug-resistant methicillin-re- sistant Staphylococcus aureus （MRSA）, Enterococ cus including vancomycin-resistant Enterococcus （ VRE ） and Acinetobacter spp. including NDM-1-haboring strains. Methods Multidrug-resistant clinical isolates were collected from our hospital between January 2009 and June 2010. Species identification was carried out using an automated system （VITEK-2）. The MICs of anti- biotics were determined using the CLSI broth dilution method, while tigecycline MICs were determined using the FDA broth microdilution method. Results About 63.9% of the 155 Acinetobacter isolates were sensitive to minocycline, 10.9% intermedi- ate and 25.2% resistant. Of the 93 strains of Enterococcus faecium, 38.8% were sensitive, 61.2% resistant to minocycline. Of the 39 Enterococcus faecalis isolates, 64.1% were sensitive to minocycline. About 66.7% of the 75 MRSA isolates were sensitive, 26. 7% intermediate and 6. 7% resistant to minocycline. All MRSA and Enterococcus isolates were sensitive to tige- cycline. Five strains of VRE and 4 strains of New Delhi metallo-beta-lactamase （NDM） 1 -producing Acinetobacter were still susceptible to tigecycline. Conclusions Tigecycline is a novel broad spectrum antimicrobial agent which is more active than mi-nocycline against the multidrug-resistant clinical isolates, including NDM-1-producing A. baumannii and VRE.

关 键 词：米诺环素 替加环素 多重耐药菌 

分 类 号：R96[医药卫生—药理学]